Clinical use:
Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (≥65 years of age): Use in the geriatric population is not associated with differences in safety or effectiveness.

RADICAVA® Oral Suspension is contraindicated in patients who are hypersensitive to the drug or any ingredient in the formulation.

Relevant warnings and precautions:

  • Neurologic events
  • Hypersensitivity reactions
  • Sulfite allergic reactions
  • Skin-related events
  • Use in pregnant and breastfeeding women

For more information:
Please consult the Product Monograph at: for important information relating to adverse reactions, drug interactions, and dosing information which has not been discussed in this piece. The Product Monograph is also available through our medical department at 1-888-212-2253